Compounds > ciprofloxacin

ciprofloxacin and amifostine anhydrous

ciprofloxacin has been researched along with amifostine anhydrous in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Andrews, C; Andric, T; Dar, S; Gezer, S; Gregory, S; Hsu, WT; Huang, RW; Lisak, L; Loew, J; Qawi, H; Raza, A; Rifkin, S; Robin, E; Venugopal, P1
Bilgi, O; Erikci, AA; Kandemir, EG; Karagoz, B; Ozturk, A; Top, C; Turken, O1

Reviews

1 review(s) available for ciprofloxacin and amifostine anhydrous

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

4 other study(ies) available for ciprofloxacin and amifostine anhydrous

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone.
    Blood, 2000, Mar-01, Volume: 95, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Amifostine; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Ciprofloxacin; Dexamethasone; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hypotension; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Pentoxifylline; Treatment Outcome

2000
Results of combination therapy with amifostine, pentoxifylline, ciprofloxacin and dexamethasone in patients with myelodysplastic syndrome and acute myeloid leukemia.
    Hematology (Amsterdam, Netherlands), 2008, Volume: 13, Issue:5

    Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Ciprofloxacin; Dexamethasone; Female; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pancytopenia; Pentoxifylline; Retrospective Studies; Treatment Outcome

2008